Status:
RECRUITING
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
Lead Sponsor:
Medical University of Vienna
Conditions:
Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
Eligibility:
All Genders
18+ years
Brief Summary
Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging. In ...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Willingness to provide written informed consent
- Diagnosis of obstructive HCM based on ESC 2023 criteria
- Planned CMR with myccardial perfusion for clinical purposes
- Receiving guideline-conform OMT
- Ability and willingness to undergo follow-up imaging and testing
- Written informed consent
Exclusion
- Claustrophobia or other contraindication for CMR imaging
- Significant coronary artery disease and/or prior stent implantation or coronary artery bypass graft surgery
- History of sudden cardiac arrest or sustained ventricular arrhythmia 12 months prior to screening
- Glomerular filtration rate \< 30ml/min/m2
- Significant hepatic impairment defined as 3x upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase; hepatic cirrhosis
- Known allergy to contrast agent
- Alternative disease causing hypertrophic cardiomyopathy (e.g. cardiac amyloidosis, Morbus Fabry)
- Pregnant women (and women with childbearing potential with desire for pregnancy)
- Breastfeeding women
- Unwillingness to comply with the study protocol and its procedures
Key Trial Info
Start Date :
September 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07150299
Start Date
September 5 2025
End Date
September 1 2027
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 2362